Clinical Verification Of Related Gene Polymorphisms And Ovarian Cancer Chemotherapy Outcome

OBJECTIVE: To explore the effect of gene single nucleotide polymorphisms(SNP)on chemosensitivity and prognosis in ovarian cancer.METHODS: The expression levels of VPS13 A,LIPG,CETN2 and ZNF582 genes were detected by QRT-PCR and immunohistochemistry.The effects of gene expression on the chemosensitivity and prognosis in ovarian cancer were evaluated,and the effect of genotype distribution frequency of candidate SNP on expression was analyzed too.RESULTS:(1)The mRNA and protein expression of VPS13 A gene in the drug-resistant group were higher than those in the sensitive group,The PFS and OS in the high protein expression group were shorter than those in the low protein expression group.(2)The mRNA and protein expression of LIPG gene were higher in the drug-resistant group than those in the sensitive group,and the PFS of the high protein expression group was shorter than that of the low protein expression group.(3)The mRNA and protein expression of CETN2 gene were not statistically significant between theresistant group and the sensitive group.The PFS of the high protein expression group was shorter than that of the low protein expression group,but had no effect on OS.(4)The mRNA expression of ZNF582 gene was not different between the resistant group and the sensitive group,and the expression level of ZNF582 gene had no effect on PFS and OS;(5)The genotype distribution frequency of rs7034531(VPS13A)and rs9958734(LIPG)had an effect on the protein expression.The genotype distribution frequency of rs20301188 CETN2 genotype had no effect on protein expression.Rs7034531(VPS13A),rs9958734(LIPG),(rs2301188)CETN2 and rs8101140(ZNF582)had no effect on mRNA expression.CONCLUSIONS: VPS13A(rs7034531)and LIPG(rs9958734)may be biomarkers that predict the sensitivity and prognosis of ovarian cancer?OBJECTIVE: To investigate the relationship between single nucleotide polymorphisms(SNP)of genes and chemotherapy sensitivity and prognosis of platinum-based chemotherapy in patients with ovarian epithelial cancer.METHODS: Twenty-four normal ovarian tissues,51 benign ovarian tissues,53platinum-sensitive tissues and 49 platinum-resistant tissues were detected by Sequenom SNP sequencing.And compare the genotype frequencies between platinum-sensitive and platinum-resistant patients.Progression free survival(PFS)and total survival time(OS)were compared in ovarian cancer patients with different genotypes too.Results: 19 SNPs were significantly correlated with chemosensitivity(P <0.05).Survival analysis showed that the frequencies of 5 SNPs(rs7786697,rs6460178,rs8101140,rs2301188 and rs3788741)were significantly correlated with PFS and OS(P <0.05).Conclusion: rs7786697,rs6460178,rs8101140,rs2301188 and rs3788741 may be a molecular marker for predicting the sensitivity and prognosis of platinum-based chemotherapy in ovarian cancer patients.Objective: To evaluate whether ERCC5 gene polymorphism is associated with response to platinum-based chemotherapy in malignant tumors and to provide evidence-based basis for clinical treatment.Methods: The effects of ERCC5 gene polymorphism on the response to platinum-based chemotherapy were analyzed in the database of Pub Med,web of science,cochrane library and Chinese CNKI.Meta analysis was performed by stata12.0 statistical software.Results: A total of13 studies were included in the study.The analysis showed that the GG genotype of the rs17655 has higher sensitivity than the CC genotype(OR=0.752,P=0.03),at the same time,the sensitivity of GG + GC genotype was higher than that of CC genotype(OR=0.823,P=0.044),The frequency of genotype distribution at rs1047768 was not associated with response to platinum-based chemotherapy.Conclusion: The genotype of rs17655 may be used as an indicator of platinum chemosensitivity.